Development and validation of high-dose methotrexate population pharmacokinetic models to inform clinical decisions on dosing
Marisa H Blackman, Bradley Yelvington, Cole Beck, Manuel Cortez, Leena Choi · 2026
Read Development and validation of high-dose methotrexate population pharmacokinetic models to inform clinical decisions on dosing by Marisa H Blackman, Bradley Yelvington, Cole Beck, Manuel Cortez, Leena Choi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13197298.txt.
Description
Marisa H Blackman and colleagues built and tested drug-level models for high-dose methotrexate in 2026. Methotrexate treats leukemia, bone cancer, and lymphoma, but slow clearing from the body can cause grave harm. A good model could guide dose choices and blood test timing.
The team built a new model from 208 adults treated at one medical center. Body size, kidney function, and sex shaped clearing in the model. Their model forecast the first blood level, at twenty-four hours, with the best accuracy and precision. Rival models did better at later times in some checks. The authors suggest a staged plan: their model first, then updated forecasts as levels come in.
Catalog record
| CREATOR | Marisa H Blackman, Bradley Yelvington, Cole Beck, Manuel Cortez, Leena Choi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |